microbi
identif
shown
result
earlier
use
appropri
antibiot
shorter
length
hospit
stay
better
outcom
decreas
overal
health
care
cost
diagnosi
persist
human
papilloma
viru
infect
follow
appropri
therapeut
intervent
reduc
incid
cervic
carcinoma
cost
treatment
attribut
morbid
mortal
new
technolog
enabl
microbiolog
investig
includ
origin
dream
nextgen
sequenc
detect
quantifi
popul
organ
patient
specimen
rais
possibl
distinguish
pathogen
organ
present
high
number
colon
gener
presum
present
lower
number
certain
colon
organ
profil
appear
correl
develop
cardiovascular
diseas
patient
colon
flora
could
analyz
profil
unfavor
bacteria
could
erad
replac
test
use
evolv
significantli
continu
thu
articl
snapshot
rapidli
chang
diagnost
microbiolog
laboratori
techniqu
space
constraint
emphasi
place
test
high
market
share
diagnost
microbiolog
technolog
person
regard
author
particularli
interest
role
specimen
process
concentr
nucleic
acid
target
remov
inhibitor
amplif
larg
neglect
despit
import
role
sensit
assay
techniqu
mention
involv
rtpcr
unless
otherwis
specifi
rtpcr
lower
incid
amplicon
contamin
laboratori
allow
mani
nucleic
acid
amplif
techniqu
come
closet
prevent
specimen
contamin
author
also
attempt
select
one
current
citat
support
point
select
arbitrari
failur
mention
public
techniqu
trade
name
constru
denigr
articl
techniqu
manufactur
first
molecular
diagnost
test
approv
food
drug
administr
fda
probe
techniqu
probe
synthes
molecular
techniqu
clinic
laboratori
perform
hybrid
detect
mani
probe
test
still
wide
use
today
fill
import
nich
involv
novel
detect
methodolog
among
first
fdaapprov
molecular
test
genprob
san
diego
ca
becam
wholli
own
subsidiari
holog
bedford
pace
probe
hybrid
protect
techniqu
diagnosi
chlamydia
trachomati
ct
neisseria
gonorrhoea
ng
patient
specimen
larg
replac
sensit
amplif
test
number
accuprob
cultur
confirm
test
remain
avail
among
mycobacterium
tuberculosi
tb
complex
mycobacterium
avium
mycobacterium
intracellular
separ
togeth
mycobacterium
kansasii
mycobacterium
gordoni
addit
test
dimorph
fungi
histoplasma
capsulatum
also
detect
h
capsulatum
var
dubosi
blastomyc
dermatididi
also
detect
paracoccidioid
brasiliensi
coccidioid
immiti
test
avail
manufactur
use
reagent
instrument
facilit
use
multipl
assay
laboratori
test
succeed
target
ribosom
rna
rrna
present
copi
per
organ
bacteri
ribosom
common
sequenc
well
genusspecif
speciesspecif
sequenc
cultur
confirm
test
remain
viabl
intend
detect
organ
visibl
coloni
liquid
medium
detect
growth
thu
amplif
step
alreadi
perform
natur
sensit
report
hologicgenprob
packag
insert
rang
develop
assay
novel
nonradioact
perform
total
solut
sampl
transfer
step
nucleic
acid
extract
hybridizationprotect
assay
base
differenti
sensit
acridinium
ester
use
distinguish
rel
labil
ester
nonhybrid
probe
stabl
form
dnarna
hybrid
detect
system
also
use
manufactur
nucleic
acid
amplif
test
naat
accuprob
assay
similar
nucleic
acid
releas
step
variabl
depend
eas
disrupt
organ
mani
laboratori
use
mycobacteri
probe
approxim
year
found
reason
argu
fdaapprov
sensit
specif
exceed
although
mycobacterium
celatum
high
concentr
also
react
tb
complex
probe
seen
year
fairfax
unpublish
data
mycobacteri
probe
test
particularli
valuabl
use
conjunct
liquid
medium
thinplat
techniqu
use
rapid
detect
identif
mycobacteria
requir
colleg
american
pathologist
northfield
il
thinplat
coloni
probe
day
detect
morpholog
use
guid
select
appropri
probe
repres
signific
time
money
save
although
elimin
need
grow
tuberculosi
suscept
test
one
visibl
coloni
probe
result
neg
whether
due
inadequ
sampl
improp
probe
select
growth
organ
recogn
probe
one
must
wait
coloni
regrow
analysi
fairfax
salimnia
unpublish
data
cultur
middlebrook
broth
must
afb
stain
confirm
presenc
mycobacteria
probe
probe
sinc
pap
smear
contribut
great
advanc
prevent
diagnosi
cervic
carcinoma
recogn
infect
human
papilloma
viru
hpv
necessari
suffici
develop
cervic
carcinoma
hpv
genotyp
exist
associ
high
risk
cervic
carcinoma
sexual
activ
women
becom
infect
hpv
infect
even
highrisk
organ
resolv
without
appar
sequella
other
progress
still
unknown
digen
hybrid
captur
qiagen
gaithersburg
md
fda
approv
primari
screen
determin
whether
women
atyp
squamou
cell
undetermin
signific
subject
culposcopi
may
use
cytyc
preservcyt
solut
cytyc
thinprep
pap
test
holog
first
step
patient
specimen
allow
react
pool
rna
probe
design
hybrid
specif
dna
highrisk
hpv
strain
antibodi
rnadna
hybrid
coat
well
microtit
plate
captur
hybrid
wash
away
unbound
specimen
reagent
detector
antihybrid
antibodi
conjug
multipl
molecul
alkalin
phosphatas
bind
captur
diagnost
molecular
microbiolog
target
amplifi
signal
colorless
substrat
alkalin
phosphatas
ad
chemiluminesc
develop
proport
amount
second
antibodi
bound
sensit
test
typic
involv
target
amplif
devis
clinic
outcom
data
avail
need
sensit
question
alreadi
shown
sensit
highli
specif
develop
cervic
intraepitheli
neoplasia
overt
malign
presenc
highrisk
dna
detect
limit
appear
associ
low
risk
malign
howev
new
inform
suggest
infect
acquir
earli
year
sexual
activ
may
reactiv
age
support
studi
sensit
assay
might
indic
also
suggest
unusu
hpv
strain
may
caus
cervic
carcinoma
precursor
lesion
restrict
popul
thu
strain
includ
assay
may
need
period
review
contrast
llq
copiesml
latest
nucleic
acid
amplif
viral
load
techniqu
see
later
articl
although
overnight
incub
standard
new
algorithm
perform
hour
publish
bdna
techniqu
resembl
molecular
tree
fig
well
microtit
plate
coat
captur
probe
bind
target
extend
target
three
hybrid
step
occur
signific
amplif
last
multipl
alkalin
phosphatasecoupl
probe
bind
branch
amplifi
probe
enzym
convert
multipl
molecul
colorless
substrat
color
end
product
allow
detect
small
number
initi
target
bdna
unaffect
amplicon
contamin
amplicon
rel
insensit
inhibitor
plagu
mani
naat
also
less
sensit
problem
result
freez
specimen
plasma
prepar
pp
tube
mode
specimen
transport
longer
recommend
amplificationbas
viral
load
determin
dna
escap
gel
matrix
pp
tube
increas
appar
viral
load
hundr
copiesml
unnotic
viral
load
routin
thousand
ten
thousand
unaccept
today
viral
load
frequent
report
see
later
articl
peptid
nucleic
acid
fluoresc
situ
hybrid
pnafish
advandx
inc
woburn
acceler
diagnosi
sepsi
common
agent
sepsi
substrat
plate
captur
probe
captur
extend
target
target
extend
preamplifi
amplifi
alk
pho
probe
product
fig
bdna
molecular
tree
techniqu
identifi
hour
blood
cultur
bottl
gram
stain
although
behav
like
standard
fish
assay
pnafish
probe
consist
uncharg
peptid
backbon
base
attach
thought
allow
probe
enter
permeabl
bacteri
cell
easili
bind
tightli
neg
charg
rrna
target
numer
public
confirm
use
techniqu
rapid
identif
common
organ
grow
blood
cultur
bottl
improv
antibiot
stewardship
shorten
length
stay
depend
patient
identif
coagulaseneg
staphylococcu
may
facilit
discontinu
antibiot
earli
discharg
salimnia
fairfax
unpublish
result
highthroughput
laboratori
blood
cultur
per
day
earli
adapt
staphylococc
enterococc
candida
probe
although
current
use
gramneg
organ
determin
test
abil
identifi
organ
cost
effect
complex
patient
popul
run
gram
posit
fungal
assay
per
shift
gener
identif
congruent
cultur
identif
microscan
walkaway
sieman
healthcar
diagnost
west
sacramento
ca
rare
miss
occur
mix
infect
due
failur
detect
low
number
staphylococcu
aureu
background
much
higher
number
coagulaseneg
staphylococcu
similar
low
number
enterococcu
faecali
background
enterococcu
spp
review
slide
previous
undetect
organ
seen
salimnia
unpublish
result
longer
occur
technologist
alert
possibl
rare
situat
pnafish
microscan
disagre
discord
result
resolv
favor
pnafish
rrna
sequenc
depend
one
resolv
result
mix
cultur
describ
previous
sensit
specif
pnafish
laboratori
approxim
redgreen
fluoresc
probe
kit
time
includ
coagulaseneg
staphylococcu
green
versu
aureu
red
enterococcu
sp
red
versu
e
faecali
green
escherichia
coli
green
versu
pseudomona
aerugenosa
red
candida
albican
green
versu
candida
glabrata
red
two
test
use
red
yellow
green
traffic
light
fluoresc
gramneg
rod
e
coli
green
klebsiella
pneumonia
yellow
p
aerugenosa
red
candida
candida
assay
c
albican
candida
parapsilosi
suscept
antifung
fluoresc
green
candida
tropicali
fluoresc
yellow
c
glabrata
candida
krusei
fluoresc
red
also
approv
test
staphylococcu
sp
versu
aureu
enterococcu
sp
versu
e
faecali
potenti
allow
report
preliminari
identif
time
gram
stain
univers
bacteri
probe
avail
analytespecif
reagent
asr
specif
probe
acinetobact
candida
dublinensi
c
parapsilosi
advandx
web
product
section
site
queri
septemb
vpiii
probe
test
becton
dickinson
bd
franklin
lake
nj
intend
diagnosi
vaginitisvaginosi
condit
caus
million
physician
visit
annual
detect
rrna
gardnerella
vaginali
use
indic
bacteri
vaginosi
bv
c
albican
trichomona
vaginali
sensit
adjust
avoid
give
posit
result
low
concentr
g
vaginali
c
albican
often
colon
normal
vagina
format
perform
cassett
superfici
resembl
later
flow
test
use
serolog
detect
influenza
rotaviru
antigen
first
fdaapprov
molecular
test
base
diagnost
molecular
microbiolog
later
flow
collect
proprietari
swab
specimen
lyse
releas
nucleic
acid
buffer
stabil
nucleic
acid
establish
stringenc
ad
cassett
incub
proper
temperatur
nucleic
acid
hybrid
cassett
contain
bead
coupl
captur
probe
analyt
plu
posit
neg
control
next
enzymelink
detector
probe
bind
specif
sequenc
target
organ
rrna
unbound
sampl
compon
probe
wash
away
colorless
substrat
convert
blue
product
suffici
target
detector
probe
bound
blue
bead
indic
posit
result
numer
public
reveal
health
care
provid
significantli
less
accur
vpiii
diagnosi
signific
candidiasi
vaginali
role
vpiii
diagnosi
bv
still
subject
debat
g
vaginali
found
presenc
absenc
bv
analysi
result
laboratori
mix
infect
common
patient
posit
vaginali
almost
posit
one
organ
fdaapprov
naat
higher
sensit
higher
price
also
avail
vaginali
hologicgenprob
section
concentr
test
give
posit
neg
result
analyt
highli
multiplex
naat
discuss
section
entitl
highli
multiplex
pcr
panel
cultur
immunoassay
probe
test
ng
ct
less
sensit
naat
naat
standard
care
sinc
late
although
certain
jurisdict
requir
cultur
legal
case
despit
rel
long
histori
naat
use
test
modal
still
undergo
signific
chang
mention
later
articl
note
updat
target
instrument
previous
publish
comparison
may
longer
appli
although
naat
gener
assum
mean
pcr
alway
case
pcr
patent
protect
innov
amplif
techniqu
develop
two
isotherm
avoid
requir
expens
thermal
cycler
stranddisplac
amplif
sda
bd
probe
tec
et
q
x
transcriptionmedi
amplif
tma
aptima
combo
holog
genprob
describ
detail
method
articl
tma
assay
target
organismspecif
rrna
sequenc
organ
rrna
ct
rrna
ng
begin
target
captur
magnet
bead
end
hybrid
protect
assay
similar
previous
describ
accuprob
test
although
speci
detector
probe
attach
differ
acrydinium
ester
one
flash
rapidli
chemiluminesc
attenu
begin
fluoresc
glow
thu
detect
sequenti
tube
bd
sda
ct
assay
target
open
read
frame
cryptic
ct
plasmid
test
complic
describ
see
method
articl
much
simpler
perform
especi
autom
instrument
manufactur
isotherm
amplif
test
sell
highthroughput
analyz
use
modifi
sda
q
x
technolog
two
pcrbase
test
roch
roch
coba
amplicor
rca
roch
molecular
diagnost
pleasonton
ca
abbott
abbott
realtim
art
abbott
molecular
de
plain
il
ctng
assay
autom
platform
also
major
player
huge
market
diagnosi
fairfax
salimnia
ct
ng
pcrbase
ct
test
origin
target
sequenc
cryptic
plasmid
older
test
fda
approv
cervic
swab
genit
swab
urin
sever
approv
physiciancollect
selfcollect
vagin
swab
tma
sda
approv
use
specimen
collect
thin
prep
pap
smear
techniqu
although
newer
version
may
yet
approv
specimen
type
prevent
contamin
sampl
nucleic
acid
amplif
must
remov
process
cytolog
sampl
cellular
analysi
specif
assay
compar
although
rca
report
detect
nongonorrhoea
neisseria
sensit
appear
adequ
genit
specimen
tma
appear
slightli
sensit
standard
sda
may
slightli
better
either
pcr
assay
gener
sensit
test
lower
ct
ng
perhap
due
lower
organ
burden
ct
highthroughput
autom
bd
sda
assay
ng
ct
probetec
q
x
perform
extract
mode
viper
system
improv
sensit
may
due
partli
target
chang
part
contamin
remov
use
magnet
ferric
oxid
beadcaptur
system
ferric
oxid
techniqu
could
generaliz
requir
presenc
specif
target
sequenc
briefli
bacteria
lyse
highph
solut
ph
lower
gener
posit
charg
ferric
oxid
particl
bind
neg
charg
nucleic
acid
particl
magnet
captur
wash
bound
dna
elut
rais
ph
extract
dna
buffer
ph
appropri
amplif
assay
recent
sever
studi
perform
extend
test
rectal
oropharyng
specimen
although
yet
fda
approv
sourc
sensit
specif
appear
adequ
except
oropharyng
ng
rca
rca
test
shown
detect
nongonorrho
neisseriacea
appropri
nongenit
test
perhap
respons
roch
introduc
new
version
std
test
coba
target
region
ng
improv
specif
also
chang
describ
later
articl
improv
abil
test
ct
yet
approv
unit
state
long
abl
continu
use
test
unclear
problem
arisen
ct
ng
ct
strain
pair
bp
delet
cryptic
plasmid
includ
origin
target
pcr
test
detect
sweden
compris
ctposit
specimen
organ
rare
rest
europ
detect
unit
state
roch
abbott
modifi
assay
includ
second
target
sequenc
roch
second
region
cryptic
plasmid
abbott
ng
resist
recommend
drug
regimen
occur
wide
use
antibiot
resist
cefepim
detect
becom
preval
unit
state
transport
kit
molecular
test
compat
cultur
suscept
test
also
significantli
less
sensit
thu
appear
molecular
analysi
specimen
test
posit
ng
may
requir
detect
antibioticresist
gene
test
commerci
avail
sequenc
best
includ
assay
remain
determin
probabl
need
chang
time
addit
test
urogenit
pathogen
ad
test
format
tma
test
vaginali
recent
fda
approv
sensit
vpiii
test
hsv
swab
extern
anogenit
lesion
also
avail
bd
q
x
format
hologicgenprob
manufactur
sever
wide
use
qualit
tmabas
microbiolog
test
includ
among
direct
test
tuberculosi
procleix
ultrio
plu
assay
ultrio
also
licens
novarti
emoryvil
ca
latter
assay
without
plu
long
approv
detect
hiv
hcv
specimen
blood
donor
organ
donor
live
deceas
intend
diagnost
workup
diseas
gener
popul
test
pool
sampl
blood
donor
unit
approv
blood
bank
test
recent
fda
approv
inclus
hbv
assay
renam
ultrio
plu
contain
sever
hiv
target
allow
detect
sever
strain
test
result
gener
neg
high
sensit
necessari
inclus
intern
control
essenti
use
flash
technolog
posit
result
give
rise
glow
see
previous
compon
posit
pool
retest
individu
assay
individu
analyt
recent
articl
contain
list
publish
rtpcr
assay
develop
detect
speci
bacteria
list
includ
multiplex
test
assay
virus
investig
acknowledg
list
incomplet
comment
laboratorydevelop
test
count
list
commerci
avail
whether
fda
approv
emphas
need
rapid
commerci
develop
fdaapprov
method
although
cyber
green
nonspecif
detector
still
use
occasion
main
molecular
detect
system
use
dual
hybrid
fluoresc
reson
energi
transfer
fret
taqman
molecular
beacon
fret
detector
consist
differ
probe
complementari
adjac
sequenc
target
amplicon
attach
differ
fluor
activ
incid
uv
light
first
fluor
emit
energi
unmonitor
wavelength
second
probe
bound
adjac
energi
transfer
second
flour
emit
light
wavelength
monitor
sensor
end
pcr
assay
melt
curv
ampliconprob
complex
gener
melt
temperatur
tm
characterist
ampliconprob
combin
mismatch
probe
amplicon
melt
temperatur
decreas
tm
differ
exploit
test
distinguish
herp
simplex
roch
pcr
primer
bind
sequenc
common
virus
within
hsv
dna
polymeras
gene
amplicon
detector
probe
match
sequenc
differ
bp
melt
curv
analysi
reveal
reproduc
tm
c
higher
exhibit
occasion
mutant
hsv
strain
detect
intermedi
melt
temperatur
report
posit
hsv
type
clear
type
could
distinguish
sequenc
amplicon
use
assay
employ
differ
target
sequenc
tm
amplicon
said
c
higher
variant
type
variant
multicod
rtx
system
use
unusu
pcr
amplif
techniqu
detector
probe
use
fluoresc
actual
decreas
amplif
progress
develop
eragen
bioscienc
inc
madison
wi
acquir
luminex
corpor
austin
tx
multicodertx
herp
simplex
viru
kit
fda
approv
multicod
rtx
assay
use
unusu
nucleotid
base
ic
ig
deoxyisoguanosid
base
pair
one
anoth
effici
incorpor
pcr
product
ig
put
end
rtx
primer
fluor
coval
link
nearbi
reaction
mix
contain
ic
coval
link
quencher
initi
cycl
amplif
ig
attach
fluor
appear
end
nascent
amplicon
strand
serv
templat
copi
direct
ic
attach
quencher
ad
end
new
strand
opposit
ig
fluor
approxim
fluor
quencher
decreas
fluoresc
melt
curv
analysi
fluoresc
increas
amplicon
melt
tm
allow
determin
natur
analyt
although
rtpcr
assay
qualit
detect
base
determin
ct
standard
rtpcr
comparison
ct
use
provid
rough
quantif
amount
target
dna
space
constraint
comment
quantit
pcr
clinic
microbiolog
confin
mainli
naat
use
hiv
viral
load
test
although
also
fdaapprov
quantit
rtpcr
assay
hcv
hbv
recent
cmv
trend
make
assay
refer
world
health
organ
intern
standard
quantit
techniqu
advanc
significantli
sinc
earli
day
alic
huang
first
demonstr
quantit
pcr
possibl
detail
discuss
review
literatur
see
fairfax
salimnia
rtpcr
inher
semiquantit
theoret
one
construct
standard
curv
copi
number
versu
ct
determin
quantiti
analyt
patient
specimen
refer
curv
howev
variat
extract
effici
presenc
inhibitor
introduc
signific
error
particularli
low
level
analyt
one
attempt
distinguish
none
one
rel
straightforward
method
overcom
problem
includ
addit
control
target
quantit
standard
qs
patient
sampl
extract
target
qs
extract
amplifi
detect
togeth
control
extract
inhibitor
present
ideal
qs
size
base
composit
target
quantifi
primer
bind
site
differ
enough
sequenc
detector
probe
probe
target
bind
detector
probe
fluoresc
differ
wavelength
target
quantit
simpl
mathemat
calcul
howev
low
target
concentr
standard
curv
longer
straight
roch
incorpor
complex
mathemat
calcul
recent
viral
load
assay
account
diverg
statist
small
number
impact
detect
fewer
target
per
reaction
mix
call
digit
pcr
exploit
specimen
multipl
reaction
conduct
small
volum
emulsifi
droplet
exampl
contain
target
wherea
other
contain
one
volum
sampl
reaction
droplet
number
posit
neg
reaction
poisson
distribut
one
calcul
number
target
origin
sampl
fdaapprov
assay
yet
base
intrigu
techniqu
convers
recent
begun
possibl
cure
hiv
infect
highli
activ
antiretrovir
therapi
improv
plasma
hiv
viral
load
techniqu
converg
discuss
ensu
evalu
residu
viru
wellcontrol
possibl
cure
individu
sensit
assay
determin
lowlevel
infect
like
assay
hiv
dna
copi
singl
cell
determin
one
replicationcompet
crucial
discuss
asid
diagnost
molecular
microbiolog
circul
cell
cell
investig
unclear
time
activ
area
investig
recent
review
strain
richman
discuss
low
level
contamin
signaltonois
ratio
pcr
test
singlecel
pcr
techniqu
beyond
scope
articl
respect
hiv
quantif
plasma
consider
affect
test
result
interpret
obviou
problem
result
increas
sensit
assay
improv
patient
told
viru
level
undetect
suddenli
quantifi
viru
timeconsum
correl
viral
load
prognosi
redon
new
sensit
assay
sequenc
differ
numer
organ
strain
inher
mutabl
organ
also
make
accur
quantif
difficult
especi
rna
virus
hiv
hcv
one
must
target
stabl
sequenc
howev
viral
rna
polymeras
enzym
error
prone
lack
proofread
activ
chang
genet
sequenc
particularli
primer
probebind
site
may
reduc
detect
viral
load
minor
quasispeci
also
caus
problem
see
later
articl
appear
one
target
necessari
futur
assay
approv
releas
diagnost
test
differ
manufactur
coordin
difficult
find
articl
compar
perform
latest
offer
differ
compani
two
current
assay
hiv
quantif
unit
state
roch
coba
ampliprep
coba
taqman
hiv
viral
load
version
abbott
realtim
assay
art
hiv
assay
differ
lower
limit
quantit
llq
cml
cml
art
hiv
introduc
difficulti
comparison
howev
compar
recent
articl
sire
colleagu
extrapol
art
hiv
curv
found
specimen
quantifi
art
hiv
could
actual
quantifi
assay
correl
well
r
although
log
higher
art
hiv
sampl
wherea
art
hiv
log
higher
whose
result
accur
remain
determin
section
focus
highli
multiplex
assay
roughli
defin
detect
target
although
mani
assay
individu
etiolog
agent
diseas
avail
test
individu
organ
often
uninform
numer
viral
bacteri
agent
respiratori
diseas
caus
similar
symptom
usual
obviou
agent
agent
infect
given
patient
even
peak
influenza
epidem
individu
may
infect
respiratori
syncyti
viru
instead
concurr
furthermor
mix
infect
common
mani
imagin
viru
infect
treatabl
other
differ
isol
requir
patient
hospit
thu
molecular
panel
could
detect
multipl
etiolog
agent
diseas
clearli
desir
four
multiplex
respiratori
panel
fda
approv
write
luminex
xtag
rvp
xrvp
rvp
fast
xrvpf
luminex
diagnost
toronto
canada
film
array
respiratori
panel
farp
biofir
diagnost
formerli
idaho
technolog
salt
lake
citi
ut
esensor
respiratori
panel
esrp
genmark
diagnost
carlsbad
ca
farp
target
includ
bacteria
one
headtohead
comparison
test
modal
recent
publish
variou
analyt
differ
sensit
specif
studi
found
esrp
sensit
analyt
compar
xrvp
second
sensit
xrvpf
similar
farp
result
requir
confirm
research
babadi
colleagu
found
farp
sensit
xrvpffor
mani
analyt
test
capabl
detect
mix
infect
ultim
final
decis
test
implement
one
laboratori
may
come
question
cost
handson
time
complex
conveni
farp
provid
result
within
hour
requir
minut
handson
time
handl
sampl
time
seem
ideal
suit
mediums
laboratori
technologist
without
special
molecular
expertis
perform
test
larger
laboratori
bought
multipl
instrument
facilit
throughput
surg
capac
may
lack
other
batch
instrument
requir
sampl
extract
test
amplicon
manipul
afterward
may
confin
pcr
laboratori
handl
sampl
per
run
none
suitabl
run
per
shift
although
stagger
technologist
start
time
could
allow
xrvpf
xrvp
esrp
requir
hour
result
problem
panel
tend
maxim
number
analyt
detect
initi
offer
base
instrument
constraint
ad
someth
new
seem
requir
someth
old
remov
latter
appar
yet
appear
unit
state
appar
high
mortal
rate
human
metapneumovirus
human
bocaviru
includ
previous
mention
assay
clear
whether
merscov
detect
coronaviru
detector
system
assay
could
distinguish
caus
common
respiratori
infect
thu
keep
panel
updat
may
prove
difficult
new
multiplex
panel
develop
viral
parasit
bacteri
agent
gastrointestin
diseas
cn
infect
biofir
assay
usual
agent
bloodstream
infect
fda
approv
august
time
appear
gastrointestin
panel
directfromthespecimen
assay
wherea
blood
cultur
panel
run
posit
cultur
bottl
may
take
day
becom
posit
detect
sever
antibiot
resist
gene
well
infect
bacteria
advanc
sequenc
technolog
known
nextgen
sequenc
ng
led
signific
advanc
basic
scienc
clinic
laboratori
medicin
includ
microbiolog
current
avail
ng
techniqu
base
use
clonal
amplicon
parallel
multistrand
sequenc
combin
highspe
highthroughput
data
analysi
made
ng
excel
tool
take
clinic
analysi
nucleic
acid
sequenc
new
level
ng
possibl
detect
quantifi
quasispeci
hiv
hcv
hbv
circul
low
level
blood
infect
patient
learn
role
develop
resist
associ
treatment
failur
difficult
imposs
use
method
mention
previous
despit
increas
number
articl
applic
ng
system
found
way
routin
clinic
microbiolog
test
lack
fda
approv
high
cost
avail
altern
diagnost
molecular
microbiolog
ng
significantli
improv
abil
studi
composit
entir
commun
microorgan
metagenom
without
organ
cultur
ng
simultan
provid
sequenc
genet
materi
member
entir
microbi
commun
analysi
data
allow
determin
rel
proport
organ
within
biom
analyz
also
determin
gene
express
metabol
pathway
util
microbi
commun
humanmicrobi
metagenom
studi
focus
understand
relationship
commens
microbi
commun
health
diseas
includ
cardiovascular
diseas
ng
also
appli
rapid
investig
outbreak
hospit
set
although
molecular
diagnost
gener
assum
impli
nucleic
acidbas
method
mass
spectroscopi
ms
use
microbiolog
sinc
time
ms
use
almost
exclus
identif
anaerob
analysi
volatil
volatil
shortchain
organ
acid
new
ms
techniqu
provid
gener
tool
identif
microorgan
grow
coloni
cultur
plate
requir
minut
potenti
improv
significantli
turnaround
time
microbiolog
cultur
report
reduc
labor
cost
especi
coupl
laboratori
autom
becom
avail
upfront
cost
high
rapid
result
impact
antibiot
usag
patient
outcom
shorten
hospit
stay
lower
total
cost
new
technolog
matrixassist
laser
desorptionion
time
flight
maldi
tof
current
maldi
tof
instrument
avail
unit
state
rapid
identif
microorgan
one
develop
shimadzu
scientif
instrument
columbia
md
licens
biomerieux
durham
nc
fdaapprov
obtain
directli
manufactur
bruker
dalton
bellerica
also
licens
siemen
healthcar
diagnost
tarrytown
ny
bd
howev
great
benefit
easi
rapid
accur
identif
microorgan
encourag
laboratori
purchas
system
perform
valid
fda
clearanc
microorgan
identif
maldi
tof
base
fact
microorgan
uniqu
protein
signatur
ps
bacteri
cell
fix
matrix
expos
laser
beam
releas
ioniz
protein
enter
vacuum
column
move
toward
detector
base
charg
mass
ps
check
match
rapidli
accumul
databas
deriv
differ
genera
speci
microorgan
differ
instrument
differ
databas
maldi
tof
identifi
microorgan
includ
aerobicanaerob
bacteria
mycobacteria
fungi
analysi
organ
tougher
cell
wall
gramposit
bacteria
yeast
fungi
appar
requir
slight
modif
procedur
hundr
abstract
articl
attest
abil
rapidli
accur
identifi
bacteria
fungi
genu
speci
level
maldi
tof
identif
etiolog
agent
sepsi
gener
perform
pathogen
first
grown
blood
cultur
bottl
subcultur
onto
standard
solid
media
step
time
consum
lead
use
broadspectrum
empir
antibiot
increas
speed
identif
protocol
develop
use
maldi
tof
directli
newli
posit
blood
cultur
bottl
data
also
accumul
illustr
abil
maldi
tof
identifi
antibioticresist
organ
howev
work
need
area
maldi
tof
could
consid
valid
altern
routin
antibiot
suscept
method
system
also
use
ms
test
abil
rapid
microorgan
identif
two
exampl
briefli
mention
laserinduc
breakdown
spectroscopi
lib
raman
spectroscopi
rs
lib
identifi
microorgan
short
time
base
determin
element
composit
system
use
strong
laser
beam
puls
atom
content
bacteri
cell
light
emit
hightemperatur
spark
collect
dispers
atom
present
specimen
identifi
peak
atom
emiss
spectrum
ratio
intens
peak
form
spectral
fingerprint
uniqu
bacteri
genu
speci
lib
spectrum
compar
databas
allow
identif
bacteri
genusspeci
rs
also
rapidli
identifi
bacteria
strain
level
use
visibl
nearinfrar
laser
provid
reproduc
molecular
spectrum
whole
bacteri
cell
uniqu
bacteri
speci
articl
prepar
articl
use
novel
techniqu
publish
chung
colleagu
use
polystyren
bead
coat
captur
probe
sequenc
common
bacteri
rrna
sequenc
asymmetr
pcr
specimen
perform
use
bacteri
rrna
target
pcr
product
captur
captur
probe
probe
organismspecif
detector
probe
complementari
speciesspecif
region
rrna
molecul
detector
probe
coval
link
magnet
nanoparticl
bound
magnet
nanoparticl
detect
faster
relax
signal
micronuclear
magnet
reson
system
assay
carri
microfluid
chip
requir
hour
carri
ml
sampl
reportedli
detect
bacteri
cell
well
multipl
infect
appli
directli
blood
aspir
bodi
fluid
adapt
detect
mrna
meca
code
enzym
respons
methicillinresist
aureu
pantonvalentin
leukocidin
found
common
communityassoci
methicillinresist
aureu
instrument
could
use
point
care
test
articl
liong
colleagu
focus
diagnosi
tuberculosi
assay
similar
one
chung
colleagu
also
perform
microfluid
chip
sputum
specimen
liquefi
load
chip
step
assay
perform
nuclear
magnet
reson
nmr
signal
relax
measur
end
assay
also
capabl
detect
mutat
associ
drug
resist
futur
research
confirm
extend
find
phase
wildest
dream
may
actual
come
true
